METASTATIC NON-SMALL CELL LUNG CANCER

This study tests whether adding the experimental drug APL-101 to the standard treatment osimertinib can help control EGFR-mutated non-small cell lung cancer that has spread. About 27 adults with advanced lung cancer who have already started osimertinib will receive the combinatio…

This study tests whether adding a new immunotherapy drug (relatlimab) to the usual nivolumab-plus-chemotherapy treatment can shrink tumors more effectively in people with advanced or recurrent non-small cell lung cancer. About 468 participants will receive either the three-drug c…

This phase 3 study tests a new combination of drugs (datopotamab deruxtecan and pembrolizumab) with or without chemotherapy for people with advanced non-small cell lung cancer who have low PD-L1 levels and have not had prior treatment. The goal is to see if this new approach work…

This early-stage trial tests whether adding two anti-inflammatory drugs (dupilumab and anakinra) to standard immunotherapy can help shrink tumors in people with advanced non-small cell lung cancer that has stopped responding to prior immunotherapy. About 33 adults will receive th…

This study tests whether adding new drugs to the cancer treatment tislelizumab (with or without chemotherapy) can shrink tumors or slow cancer growth in people with advanced non-small cell lung cancer who haven't had treatment before. About 400 participants will join, split into …

This trial aimed to test a new treatment for people with metastatic non-small cell lung cancer. Doctors would take immune cells from a patient's tumor, use CRISPR gene editing to make them stronger, and then put them back into the patient. The goal was to see if these edited cell…

This study compares a new shot form of the immunotherapy drug pembrolizumab (given with chemo) to the standard IV version for adults in Japan with metastatic non-small cell lung cancer who haven't had treatment before. The main goal is to see if the shot provides similar drug lev…

This study compares a new shot form of the immunotherapy drug pembrolizumab (given under the skin) to the standard IV version, both combined with chemotherapy, for people with advanced non-small cell lung cancer that hasn't been treated before. About 377 adults will take part to …

This study tests whether a new drug called volrustomig, combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has spread. About 1,200 participants whose tumors have low leve…

This study tests whether adding ramucirumab to the standard drug erlotinib helps people with a specific type of advanced lung cancer (EGFR mutation-positive) live longer without their cancer growing. About 545 people who had not yet received treatment took part. The goal is to se…

This study tests whether a simple blood test can tell if a lung cancer drug (pembrolizumab) is working early on. About 40 people with stage IV non-small cell lung cancer will have blood drawn at different times. If the test shows the drug isn't working well, patients may switch t…

This early-stage study tests a drug called furmonertinib in 160 people with advanced lung cancer that has certain gene mutations (EGFR or HER2). The goal is to see if the drug is safe and can shrink tumors. Participants have already tried other treatments without success.

This study tests two drug combinations (Tedopi plus docetaxel or Tedopi plus nivolumab) as a second treatment option for people with advanced non-small-cell lung cancer whose cancer worsened after initial chemo-immunotherapy. About 105 adults with a specific genetic marker (HLA-A…